Serum Malondialdehyde (MDA) as Predictor for Severity of Coronary Artery Disease (CAD) | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 140, Volume 95, Issue 1, April 2024, Pages 2206-2211 PDF (596.24 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2024.360963 | ||
| Abstract | ||
| Background: Coronary artery disease (CAD) occurs when the heart's myocardium receives an insufficient blood and oxygen supply. Objective: This study aimed to measure serum malondialdehyde (MDA) levels in CAD patients and examine their association with the disease's severity. Patients and Methods: This cross-sectional observational study involved 75 patients who underwent diagnostic coronary angiography to diagnose CAD. Patients were categorized into three groups based on their SYNTAX scores: the first group had mild CAD (SYNTAX score: ≤22), the second group had moderate CAD (SYNTAX score: 23-32), and the third group had severe CAD (SYNTAX score: ≥33). Results: The optimal MDA cutoff point for distinguishing between low and intermediate risk was >279.5 ng/ml, with a sensitivity of 83.3% and a specificity of 58.9%. The area under the curve (AUC) was 0.796, which was statistically significant (p=0.001). For differentiating between intermediate and high risk, the best MDA cutoff point was >342 ng/ml, with a sensitivity of 85.7% and a specificity of 91.7%. The AUC was 0.988, which was statistically significant (p < 0.001). Conclusion: Serum MDA levels could serve as a non-invasive biomarker to assess the severity of CAD, aligning with the findings from coronary angiography. | ||
| Keywords | ||
| Serum Malondialdehyde; Coronary Artery Disease; Disease Severity | ||
|
Statistics Article View: 88 PDF Download: 146 |
||
